Study of the Link Between Complement Activation and IgA Nephropathy Severity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Strasbourg, France
About this trial
ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study.
The main objective is to evaluate the relevance of complement activation as a biomarker of disease severity and progression in patients with a biopsy proven IgAN.
Eligibility criteria
Qualifiers
Adult patients, male or female, with a biopsy proven IgA nephropathy.
Primitive and secondary forms can be included
Regardless of the date of diagnosis and the level of kidney function
With or without past of kidney transplantation
Disqualifiers
Active or recent infectious or inflammatory syndrome (<2 months), recent vaccination (<2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (<2 months), current treatment with complement inhibitors
Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.)
Subject under safeguard of justice, guardianship or curatorship
Trial design
Treatments tested in this trial
- IgAN patients
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov